Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Short term Debt (2016 - 2022)

Historic Short term Debt for Spero Therapeutics (SPRO) over the last 5 years, with Q3 2022 value amounting to $141000.0.

  • Spero Therapeutics' Short term Debt changed N/A to $141000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $141000.0, marking a year-over-year change of. This contributed to the annual value of $223000.0 for FY2018, which is 0.0% changed from last year.
  • Per Spero Therapeutics' latest filing, its Short term Debt stood at $141000.0 for Q3 2022.
  • Over the past 5 years, Spero Therapeutics' Short term Debt peaked at $995000.0 during Q1 2022, and registered a low of $115000.0 during Q2 2022.
  • For the 3-year period, Spero Therapeutics' Short term Debt averaged around $281200.0, with its median value being $223000.0 (2018).
  • Over the last 5 years, Spero Therapeutics' Short term Debt had its largest YoY gain of 276.5% in 2018, and its largest YoY loss of 0.0% in 2018.
  • Spero Therapeutics' Short term Debt (Quarter) stood at $223000.0 in 2018, then changed by 0.0% to $223000.0 in 2019, then tumbled by 36.77% to $141000.0 in 2022.
  • Its last three reported values are $141000.0 in Q3 2022, $115000.0 for Q2 2022, and $995000.0 during Q1 2022.